[Perinatal hemolytic disease. Part 2: Prevention and management].
There has been a dramatic reduction in the incidence of neonatal mortality due to fetal hemolytic disease since the introduction of Rhesus prophylaxis. Although routinely used since 1968, the exact mode of action of anti-D IgGs is still not fully understood. Notable advances have taken place in the screening and the management of fetal hemolytic disease. This article describes the antibody detection in the mother, and the fetal management with ultrasound amniocentesis, fetal blood sampling and intrauterine transfusions. Finally, the postnatal management is also considered.
Hohlfeld
P
P
Département de Gynécologie et Obstétrique, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Suisse.
Wirthner
D
D
Tissot
J D
JD
D000465:Algorithms; D003663:Decision Trees; D004899:Erythroblastosis, Fetal / Q000175:diagnosis* / Q000209:etiology / Q000517:prevention & control*; D006801:Humans; D007231:Infant, Newborn; D011181:Postnatal Care; D011296:Prenatal Diagnosis / Q000379:methods*; D018029:Rho(D) Immune Globulin / Q000627:therapeutic use*
D018029:Rho(D) Immune Globulin
Maladie hémolytique périnatale. 2e Partie: Prévention et prise en charge.